Early Options: Module 1 Post-Module Test

Early Options - A Provider's Guide to Medical Abortion

We strongly urge you to print out these CME Post-Test Questions before starting this module to help guide you through the material. You will have the opportunity to answer the questions on-line at the end of each module.

1. The FDA-approved ("standard") regimen for medical abortion is:

A. Mifepristone 600 mg PO followed 2 days later by misoprostol 400 µg PV for pregnancies up to 49 days' gestation

B. Mifepristone 600 mg PO followed 2 days later by misoprostol 400 µg PO for pregnancies up to 63 days' gestation

C. Mifepristone 400 mg PO followed 2 days later by misoprostol 600 µg PO for pregnancies up to 49 days' gestation

D. Mifepristone 600 mg PO followed 2 days later by misoprostol 400 µg PO for pregnancies up to 49 days' gestation

2. The success rate (complete abortion without the need for surgery) of the standard FDA-approved mifepristone/misoprostol regimen in gestations of ≤ 49 days is:

A. 87% to 92%

B. Less than 92%

C. Greater than 97%

D. 92% to 97%

3. All of the following statements regarding the acceptability of medical abortion are true except:

A. Surveys indicate that one third of ob-gyns currently providing abortion services would not provide medical abortion services.

B. Clinicians' opinions about medical abortion tend to improve over time.

C. Women cite greater "naturalness" as an advantage of medical over surgical abortion.

D. Medical abortion has been rated "satisfactory" or "very satisfactory" by 88% to 97% of women.

4. All of the following statements regarding vaginal versus oral misoprostol are true except:

A. After oral dosing, plasma levels peak at around 30 minutes and drop off sharply within 2 hours.

B. Following vaginal administration, plasma levels peak at around 80 minutes and remain relatively high for 4 hours.

C. Compared to oral misoprostol, vaginal misoprostol is associated with a more rapid expulsion of the conceptus.

D. The incidence of vomiting and diarrhea is significantly higher among women receiving vaginal misoprostol.

5. Comparison of methotrexate/misoprostol and the standard mifepristone/misoprostol regimen when used through 49 days' gestation demonstrates:

A. The two regimens achieve approximately equal efficacy by 4 weeks after initiation of the treatment.

B. More women will abort earlier with mifepristone/misoprostol.

C. Both regimens are potentially teratogenic.

D. All of the above

Click here to return to Module 1 - Pharmacological Approaches to Early Abortion.